Download PDF
CC BY 4.0 · Ibnosina Journal of Medicine and Biomedical Sciences
DOI: 10.1055/s-0045-1809148
Original Article

Association between CYP2A13 Polymorphisms and Lung Cancer Risk: A Systematic Review and Meta-Analysis of Case–Control Studies

Fui-Ling Voon 
1   Faculty of Resource Science and Technology, University of Malaysia, Sarawak, Kota Samarahan, Malaysia
,
Edmund Ui-Hang Sim 
1   Faculty of Resource Science and Technology, University of Malaysia, Sarawak, Kota Samarahan, Malaysia
› Author Affiliations Funding and Sponsorship This study was supported by the Sarawak Digital Economy Corporation (SDEC) Berhad's Translational Research Grant Programme, grant number: IRG/F07/SDEC/85162/2022.
› Further Information
Also available at
   Permissions and Reprints

Abstract

Objectives

Lung cancer remains a leading cause of cancer-related deaths worldwide, with cigarette smoking as a major risk factor. Genetic variations in the cytochrome P450 family, particularly CYP2A13 polymorphisms, have been suggested to influence lung cancer susceptibility. However, their role remains unclear, particularly in relation to smoking status and regional populations differences. This systematic review and meta-analysis aimed to evaluate the association between CYP2A13 combination and homozygous variants and lung cancer risk, stratified by smoking status and geographic region.

Materials and Methods

A comprehensive search of electronic databases (PubMed, ScienceDirect, SCOPUS, and Google Scholar) was conducted up to November 11, 2024, to identify eligible case–control studies on CYP2A13 polymorphisms and lung cancer. Inclusion and exclusion criteria were based on exposure of interest, study design, language, type of publication, and reported outcome. Data from 10 studies (2,853 lung cancer cases and 3,651 controls) were pooled to calculate odds ratios (OR) with 95% confidence intervals (CIs), using a random-effects model. Subgroup analyses were performed by smoking status and geographic region. Publication bias was assessed using Egger's test and funnel plots.

Results

A significant association was observed between CYP2A13 polymorphisms and lung cancer risk in specific populations. In East Asian populations, the homozygous variant was associated with an increased lung cancer risk (pooled OR: 1.37, 95% CI: 1.13–1.66). Among smokers in Europe, the combination variant showed a pooled OR of 1.64 (95% CI: 1.21–2.23). In East Asian smokers, the homozygous variant had a pooled OR of 1.52 (95% CI: 1.17–1.96). No significant publication bias was detected.

Conclusion

This meta-analysis suggests that CYP2A13 polymorphisms may contribute to lung cancer susceptibility, with smoking serving as a key modifier. The findings are particularly relevant in East Asian and European populations, but given the heterogeneity between studies and limited sample sizes, further large-scale investigations are necessary. These insights provide a foundation for future research on CYP2A13 as a potential biomarker for lung cancer risk.

Keywords

CYP2A13 - lung cancer - genetic polymorphism - smoking - meta-analysis - East Asian - European

Data Availability Statement

The data used in this meta-analysis were obtained from publicly available case–control studies. All relevant data are cited within the manuscript, and the studies included in the analysis are referenced in the reference list. There are no additional datasets beyond those provided by the original studies.


Authors' Contributions

E.U-H.S. and F-L.V. conceptualized and designed the study. F-L.V. extracted the data and carried out the statistical analysis with support from E.U-H.S. Both authors have full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. F-L.V. produced an initial draft of the manuscript and subsequent revisions to it. E.U-H.S. and F-L.V. critically revised the manuscript for important intellectual content. Both authors approved the final version.


Compliance with Ethical Principles

The authors confirm that this review has been prepared in accordance with COPE guidelines and regulations. Given the nature of this article, ethical approval is not required.


Supplementary Material



Publication History

Article published online:
13 May 2025

© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Bade BC, Dela Cruz CS. Lung cancer 2020: epidemiology, etiology, and prevention. Clin Chest Med 2020; 41 (01) 1-24
    CrossrefPubMedSearch in Google Scholar
  • 2 Raunio H, Rahnasto-Rilla M. CYP2A6: genetics, structure, regulation, and function. Drug Metabol Drug Interact 2012; 27 (02) 73-88
    PubMedSearch in Google Scholar
  • 3 Smith BD, Sanders JL, Porubsky PR, Lushington GH, Stout CD, Scott EE. Structure of the human lung cytochrome P450 2A13. J Biol Chem 2007; 282 (23) 17306-17313
    PubMedSearch in Google Scholar
  • 4 Chiang HC, Wang CK, Tsou TC. Differential distribution of CYP2A6 and CYP2A13 in the human respiratory tract. Respiration 2012; 84 (04) 319-326
    PubMedSearch in Google Scholar
  • 5 Hecht SS. Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. Chem Res Toxicol 1998; 11 (06) 559-603
    PubMedSearch in Google Scholar
  • 6 Chiang HC, Wang CY, Lee HL, Tsou TC. Metabolic effects of CYP2A6 and CYP2A13 on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced gene mutation–a mammalian cell-based mutagenesis approach. Toxicol Appl Pharmacol 2011; 253 (02) 145-152
    PubMedSearch in Google Scholar
  • 7 Su T, Bao Z, Zhang QY, Smith TJ, Hong JY, Ding X. Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res 2000; 60 (18) 5074-5079
    PubMedSearch in Google Scholar
  • 8 Fukami T, Nakajima M, Matsumoto I, Zen Y, Oda M, Yokoi T. Immunohistochemical analysis of CYP2A13 in various types of human lung cancers. Cancer Sci 2010; 101 (04) 1024-1028
    PubMedSearch in Google Scholar
  • 9 Sun L, Fan X. Expression of cytochrome P450 2A13 in human non-small cell lung cancer and its clinical significance. J Biomed Res 2013; 27 (03) 202-207
    PubMedSearch in Google Scholar
  • 10 Wang H, Tan W, Hao B. et al. Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK. Cancer Res 2003; 63 (22) 8057-8061
    PubMedSearch in Google Scholar
  • 11 Ramadhani N, Soeroso NN, Tarigan SP, Eyanoer PC, Hidayat H. Correlation between genetic polymorphism of CYP2A13 genotype and lung cancer in female passive smokers. Molecular and Cellular Biomedical Sciences 2022; 6 (02) 89
    Search in Google Scholar
  • 12 Kiyohara C, Takayama K, Nakanishi Y. CYP2A13, CYP2A6, and the risk of lung adenocarcinoma in a Japanese population. J Health Sci 2005; 51 (06) 658-666
    Search in Google Scholar
  • 13 Hua F, Guo Y, Sun Q, Yang L, Gao F. HapMap-based study: CYP2A13 may be a potential key metabolic enzyme gene in the carcinogenesis of lung cancer in non-smokers. Thorac Cancer 2019; 10 (04) 601-606
    PubMedSearch in Google Scholar
  • 14 Pathak AK, Husain N, Kant S, Bala L. Independent and interactive effect of CYPs and GSTs genetic variants and tobacco smoking on the risk of non-small cell lung carcinoma. Arch Med Res 2021; 52 (07) 719-730
    PubMedSearch in Google Scholar
  • 15 Cao Y, Miao XP, Zeng YX, Lin DX, Shao JY. Association between genetic polymorphisms of CYP2A13, CYP2A6 and risk of nasopharyngeal carcinoma in southern Chinese population. Cancer Biology 2011;1(1)
  • 16 Jiang JH, Jia WH, Chen HK. et al. Genetic polymorphisms of CYP2A13 and its relationship to nasopharyngeal carcinoma in the Cantonese population. J Transl Med 2004; 2 (01) 24
    PubMedSearch in Google Scholar
  • 17 Kumondai M, Hosono H, Orikasa K. et al. CYP2A13 genetic polymorphisms in relation to the risk of bladder cancer in Japanese smokers. Biol Pharm Bull 2016; 39 (10) 1683-1686
    PubMedSearch in Google Scholar
  • 18 Song DK, Xing DL, Zhang LR, Li ZX, Liu J, Qiao BP. Association of NAT2, GSTM1, GSTT1, CYP2A6, and CYP2A13 gene polymorphisms with susceptibility and clinicopathologic characteristics of bladder cancer in Central China. Cancer Detect Prev 2009; 32 (5-6): 416-423
    PubMedSearch in Google Scholar
  • 19 Mohelnikova-Duchonova B, Vrana D, Holcatova I, Ryska M, Smerhovsky Z, Soucek P. CYP2A13, ADH1B, and ADH1C gene polymorphisms and pancreatic cancer risk. Pancreas 2010; 39 (02) 144-148
    CrossrefPubMedSearch in Google Scholar
  • 20 Moher D, Shamseer L, Clarke M. et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Revista Espanola de Nutricion Humana y Dietetica 2016; 20 (02) 148-160
    CrossrefPubMedSearch in Google Scholar
  • 21 Sim CC, Sim EUH. Over-expression of cyclo-oxygenase-2 predicts poor survival of patients with nasopharyngeal carcinoma: a meta-analysis. J Laryngol Rhinol Otol 2020; 134 (04) 338-343
    Search in Google Scholar
  • 22 Wells G, Shea B, O'Connell D. et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Accessed April 17, 2025 at: https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
  • 23 Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315 (7109) 629-634
    CrossrefPubMedSearch in Google Scholar
  • 24 R Core Team. R: A language and environment for statistical computing. Published online 2023. Accessed October 18, 2023 at: https://www.R-project.org/
  • 25 Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health 2019; 22 (04) 153-160
    CrossrefPubMedSearch in Google Scholar
  • 26 Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw 2010; 36 (03) 1-48
    CrossrefSearch in Google Scholar
  • 27 Cheng XY, Chen GL, Zhang WX, Zhou G, Wang D, Zhou HH. Arg257Cys polymorphism of CYP2A13 in a Chinese population. Clin Chim Acta 2004; 343 (1-2): 213-216
    PubMedSearch in Google Scholar
  • 28 Chiang HC, Lee H, Chao HR, Chiou YH, Tsou TC. Pulmonary CYP2A13 levels are associated with early occurrence of lung cancer-Its implication in mutagenesis of non-small cell lung carcinoma. Cancer Epidemiol 2013; 37 (05) 653-659
    PubMedSearch in Google Scholar
  • 29 Soeroso NN, Zain-Hamid R, Sinaga BY, Sadewa AH. The CYP2A13 Arg257Cys polymorphism in Bataknese lung cancer patients and its relationship with nicotine dependence. National Published Articles 2017; 1-7
    Search in Google Scholar
  • 30 Timofeeva MN, Kropp S, Sauter W. et al; LUCY-Consortium. CYP450 polymorphisms as risk factors for early-onset lung cancer: gender-specific differences. Carcinogenesis 2009; 30 (07) 1161-1169
    PubMedSearch in Google Scholar
  • 31 Soeroso NN, Sinaga BYM, Zain-Hamid R, Sadewa AH, Syahruddin E. The CYP2A13 Arg257Cys polymorphism and its relationship to lung cancer. Stem Cell Oncology 2018; 265-269
    Search in Google Scholar
  • 32 Cauffiez C, Lo-Guidice JM, Quaranta S. et al. Genetic polymorphism of the human cytochrome CYP2A13 in a French population: implication in lung cancer susceptibility. Biochem Biophys Res Commun 2004; 317 (02) 662-669
    PubMedSearch in Google Scholar
  • 33 Tamaki Y, Arai T, Sugimura H. et al. Association between cancer risk and drug-metabolizing enzyme gene (CYP2A6, CYP2A13, CYP4B1, SULT1A1, GSTM1, and GSTT1) polymorphisms in cases of lung cancer in Japan. Drug Metab Pharmacokinet 2011; 26 (05) 516-522
    PubMedSearch in Google Scholar